RESULTS: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(-) TNBC in patients not receiving chemotherapy (P=0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(-) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for a...
Patients withTP53-mutated tumor are younger than patients withTP53wild-type LGG (p= 0.01), but there is no difference considering gender. The current study included 61 LGG: (i) 32 WHO grade II oligodendrogliomas, (ii) 8 WHO gra...
DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS: Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet, 105: 93-102, 1998.DiCioccio, R. A. et al. (1998) Correlation of TP53 muta- tions and p53 expression in ovarian tumors. Cancer Genet Cyto...
and poorly differentiation group Was 40.43%,the difference was statistically significant(P<0.05).There was no significant difference of the deletion rate of TP53 gene in different tumor invasion depth and lymphnode metastasis status fP>0.05).There was no sigmficant difference of the degree of p53 ...
The tumour suppressor gene TP53 (also known as p53) is critical for cell cycle control and apoptosis. TP53 status has been described as a prognostic factor associated with worse outcome in a variety of malignancies, including breast cancer, in which TP53 mutations or increased levels of protein ...
These <12% TP53 mutated cases were enriched for BRAF and FBXW7 mutations (Table S7). TP53 mutations could be further subdivided into those with < 12% VAF (n = 16) or ≥12% VAF (n = 43), with no difference in the site or type of TP53 mutation between subgroups (Fig...
Remarkably, we also uncover an additional synthetic lethality between ENDOD1 and p53. ENDOD1 depletion in TP53 mutated tumour cells, or p53 depletion in ENDOD1−/− cells, results in rapid single stranded DNA accumulation and cell death. Because TP53 is mutated in ~50% of tumours, ENDOD1...
. Several small molecule compounds have been recently developed targeting the MDM2-p53 axis to reactivate the tumor suppressor activity of p53. RG7388, also known as Idasanutlin, is a highly potent and selective second-generation MDM2 inhibitor which blocks the interaction between MDM2 and p53 [20...
In a recent analysis of the database, we showed that that loss of TA capacity is a key factor for the selection of missense mutations, and that difference in mutation frequencies is closely related to nucleotide substitution rates along TP53 coding sequence. TA capacity of inherited missense ...
TP53 CNloss correlated with cytogenetic risk groups (P < .001) and was predictably significantly more common in AML with complex cytogenetics (210/260; 80.8% vs 9/52; 17.3%; P < .001). Of note, there was no significant difference between TP53 CNloss and CNintact cases in terms of ...